Claims for Patent: 11,617,728

Summary for Patent: 11,617,728

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/693,711
Patent Claims:	1. A method of treating major depressive disorder, comprising administering a dosage form by mouth once daily or twice daily to a human patient in need thereof, wherein the dosage form comprises about 105 mg of bupropion hydrochloride and about 45 mg of a dextromethorphan salt as the only therapeutically active compounds in the dosage form. 2. The method of claim 1, wherein the dosage form is a tablet. 3. The method of claim 1, wherein bupropion hydrochloride is in a sustained release formulation. 4. The method of claim 3, wherein the dextromethorphan salt is in an immediate release formulation. 5. The method of claim 1, wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the Cmax of bupropion is about 9×101 ng/mL. 6. The method of claim 1, wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC0-12 of bupropion is about 7×102 ng·hr/mL. 7. The method of claim 1, wherein the human patient is an extensive CYP2D6 metabolizer. 8. The method of claim 7, wherein the dosage form is a tablet. 9. The method of claim 7, wherein bupropion hydrochloride is in a sustained release formulation. 10. The method of claim 9, wherein the dextromethorphan salt is in an immediate release formulation. 11. The method of claim 7, wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the Cmax of bupropion is about 9×101 ng/mL. 12. The method of claim 7, wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC0-12 of bupropion is about 7×102 ng·hr/mL. 13. The method of claim 1, wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter. 14. The method of claim 13, wherein the human patient is an extensive CYP2D6 metabolizer. 15. The method of claim 13, wherein the dosage form is a tablet. 16. The method of claim 13, wherein bupropion hydrochloride is in a sustained release formulation. 17. The method of claim 16, wherein the dextromethorphan salt is in an immediate release formulation. 18. The method of claim 15, wherein the dosage form is administered for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the Cmax of bupropion is about 9×101 ng/mL. 19. The method of claim 15, wherein the dosage form is administered for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC0-12 of bupropion is about 7×102 ng·hr/mL. 20. A method of treating major depressive disorder, comprising administering a dosage form by mouth once daily or twice daily to a human patient in need thereof, wherein the dosage form consists essentially of about 105 mg of bupropion hydrochloride and about 45 mg of a dextromethorphan salt. 21. A method of treating major depressive disorder, comprising orally administering a dosage form no more than twice daily to a human patient in need thereof, wherein the therapeutically active compounds in the dosage form consist of (i) about 105 mg of bupropion hydrochloride and (ii) about 45 mg of a dextromethorphan salt.